Poynter, Harki appointed to leadership team at Masonic Cancer Center

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Jenny Poynter and Daniel Harki were appointed to the leadership team of Masonic Cancer Center April 15.

Poynter was named Masonic Cancer Center’s first associate director for Community Outreach and Engagement. Poynter is an associate professor in the Department of Pediatrics, Division of Epidemiology and Clinical Research of the Medical School at the University of Minnesota. She also serves as the vice chair of the Children’s Oncology Group Epidemiology Committee and is a research member of the Masonic Cancer Center’s Screening, Prevention, Etiology, and Cancer Survivorship Program.

She will be joining Chris Pennell, the center’s associate director for Community Outreach and Education. That role will be divided into two associate director roles. Poynter is the associate director of Community Outreach, and Pennell will assume the position of associate director for Education.

Poynter is a molecular epidemiologist whose research is focused on genetic susceptibility and epigenetic alterations in pediatric germ cell tumors and myeloid malignancy.

Harki, an associate professor in the Department of Medicinal Chemistry within the College of Pharmacy at University of Minnesota, will become a co-leader of the Masonic Cancer Center, University of Minnesota’s Cellular Mechanisms Program. He will join Carol Lange, professor in the Department of Medicine, Division of Hematology-Oncology and Transplantation within the Medical School.

Harki succeeds long time co-leader James McCarthy, professor in the Department of Laboratory Medicine and Pathology in the Medical School.

Harki has published widely on the development of novel small molecules, nucleosides and nucleic acids, and in particular, his program focuses significant efforts developing chemical probes for the APOBEC family of DNA cytosine deaminases.

Table of Contents

YOU MAY BE INTERESTED IN

The University of California, San Francisco and global oncology communities mourn the death of Felix Y. Feng, MD, a radiation oncologist and a leading figure in genitourinary cancer research. A professor of radiation oncology, urology and medicine, and vice chair of translational research at the UCSF Helen Diller Family Comprehensive Cancer Center, Feng died from cancer on Dec.10, 2024. He was 48.
The late Felix Feng, MD (center) with researchers Jonathan Chou, MD, PhD (left) and Lisa Chesner, PhD (right), in 2019.Photo by Noah BergerFelix Y. Feng, a genitourinary cancer research leader, died on Dec. 10, 2024. He was 48.This article is republished with permission by NRG Oncology.Dr. Feng was the former NRG Oncology Genitourinary Cancer Committee chair and an RTOG Foundation member. After years of dedicated and enthusiastic commitment to the NRG and previously the RTOG Genitourinary Cancer Committee, chairing or co-chairing 13 research protocols for NRG and RTOG, Dr. Feng was appointed committee chair in March 2018, following in the footsteps of Dr. Howard Sandler, his mentor. Dr. Feng was also a member of the RTOG Foundation Board of Directors.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login